Bio-Medical Applications Of North Carolina, Inc. in Louisburg, North Carolina - Dialysis Center

Bio-Medical Applications Of North Carolina, Inc. is a medicare approved dialysis facility center in Louisburg, North Carolina and it has 4 dialysis stations. It is located in Franklin county at 935 North Main Street, Louisburg, NC, 27549. You can reach out to the office of Bio-Medical Applications Of North Carolina, Inc. at (919) 497-0180. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Bio-Medical Applications Of North Carolina, Inc. has the following ownership type - Profit. It was first certified by medicare in December, 2016. The medicare id for this facility is 342715 and it accepts patients under medicare ESRD program.

Dialysis Center Profile

NameBio-Medical Applications Of North Carolina, Inc.
Location935 North Main Street, Louisburg, North Carolina
No. of Dialysis Stations 4
Medicare ID342715
Managed ByFresenius Medical Care
Ownership TypeProfit
Late Shifts No

Contact Information


935 North Main Street, Louisburg, North Carolina, 27549
(919) 497-0180
Not Available

Map and Direction



NPI Associated with this Dialysis Facility:

Dialysis Facilities may have multiple NPI numbers. We have found possible NPI number/s associated with Bio-Medical Applications Of North Carolina, Inc. from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number1124473590
Organization NameFresenius Kidney Care Tar River
Doing Business AsBio-medical Applications Of North Carolina, Inc.
Address935 N Main Street Louisburg, North Carolina, 27549
Phone Number(919) 497-0180

Patient Distribution

Anemia Management

Dialysis patients with Hemoglobin data6

Dialysis Adequacy

Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.

  • Hemodialysis
    Adult patients getting regular hemodialysis at the center20
    Adult patient months included in Kt/V greater than or equal to 1.2101
    Percentage of adult patients getting regular hemodialysis at the center98
    Percentage of pediatric patients getting regular hemodialysis at the center
  • Peritoneal Dialysis
    Adult patients getting regular peritoneal dialysis at the center2
    Adult patient months included in Kt/V greater than or equal to 1.715
    Percentage of adult patients getting regular peritoneal dialysis at the center
    Percentage of pediatric patients getting regular peritoneal dialysis at the center

Mineral and Bone Disorder

An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Bio-Medical Applications Of North Carolina, Inc. with elevated calcium levels.

Patients with hypercalcemia23
Hypercalcemia patient months125
Hypercalcemia patients with serumcalcium greater than 10.2 mg1
Patients with Serumphosphor25
Patients with Serumphosphor less than 3.5 mg/dL9
Patients with Serumphosphor from 3.5 to 4.5 mg/dL20
Patients with Serumphosphor from 4.6 to 5.5 mg/dL26
Patients with Serumphosphor from 5.6 to 7 mg/dL33
Patients with Serumphosphor greater than 7 mg/dL12

Vascular Access

The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.

Patients included in arterial venous fistula and catheter summaries 18
Patient months included in arterial venous fistula and catheter summaries 72
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment54